Linaclotide

World Peptide Foundation

WORLD PEPTIDEFOUNDATION

The Human Peptide Project™

Contribute an Observation

WPF flagship programsThe Human Peptide Project™The Living Peptide Record™

English

Loading public peptide profiles…Open the Master Registry

Linaclotide — Peptide Scientific Intelligence

What we know

Evidence, claims, and boundaries

The project separates represented evidence from qualification, contradiction, uncertainty, and what the evidence does not establish.

Reconciled domain conclusions

6 conclusions connected to 0 featured studies

Linaclotide no longer relies on the legacy “no public claim” state. Each research domain publishes a bounded conclusion, confidence level, evidence synthesis, limitations, geographic applicability, regulatory interpretation, and research gaps.

Inspect the reconciled evidence atlas

Evidence boundary

Featured evidence

Domain links

See graph

Contradicting

With explicit limits

What this does not establish

• WPF’s atlas lists work in chronic constipation and pediatric functional constipation, plus trials and reviews of linaclotide as an adjunct in colonoscopy preparation. Bowel-cleansing outcomes do not automatically establish relief of a chronic condition, and subgroup or post hoc findings need their own limits.
• The Directory has no published source-linked citations or jurisdiction-specific regulatory record here. Efficacy, adverse events, pediatric applicability, and approved indications require primary and official sources rather than a pooled screening list.
• The presence of published evidence does not by itself establish safety, efficacy, causation or clinical benefit.

Inspect the published evidence record157 governed records · titles, provenance, and original-source linksOpen records ↓

2024Phase 3 human evidence

Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Content-verified record concerning Linaclotide: "Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial." Abstract excerpt: Linaclotide, a guanylate cyclase C agonist, has been approved in the USA for the treatment of chronic idiopathic constipation and irritable bowel syndrome with predominant constipation in adults. We aimed to assess the efficacy and safety of linaclotide in paediatric patients aged 6-17 years with functional constipation. This randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Source: peer_reviewed_research
DOI: 10.1016/s2468-1253(23)00398-9
PubMed: 38211604

Open original source

2024Phase 3 human evidence

Linaclotide for functional constipation in paediatric patients: phase III results.

Research

How the scientific record is developing

Chronology, unresolved research questions, opportunities, and researcher activity remain descriptive rather than evaluative.

Research chronology

2006 · study · Temporal status not established
Linaclotide
other
2007 · study · Temporal status not established
Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
peer_reviewed_research
2007 · study · Temporal status not established
Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.
peer_reviewed_research
2009 · study · Temporal status not established
Pilot study on the effect of linaclotide in patients with chronic constipation.
peer_reviewed_research
2010 · study · Temporal status not established
Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.
peer_reviewed_research
2010 · study · Temporal status not established
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
peer_reviewed_research
2010 · study · Temporal status not established
Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
peer_reviewed_research
2010 · study · Temporal status not established
Molecule of the month. Linaclotide acetate.
peer_reviewed_research
2010 · study · Temporal status not established
Efficacy of linaclotide for patients with chronic constipation.
peer_reviewed_research
2010 · study · Temporal status not established
Linaclotide - a secretagogue and antihyperalgesic agent - what next?
peer_reviewed_research
2010 · study · Temporal status not established
Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.
peer_reviewed_research
2010 · study · Temporal status not established
Constipation: Linaclotide--a stimulating new drug for chronic constipation.
peer_reviewed_research
2011 · study · Temporal status not established
Two randomized trials of linaclotide for chronic constipation.
peer_reviewed_research
2011 · study · Temporal status not established
Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
peer_reviewed_research
2011 · study · Temporal status not established
Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide.
peer_reviewed_research
2011 · study · Temporal status not established
The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
peer_reviewed_research
2011 · study · Temporal status not established
Linaclotide: a novel approach to the treatment of irritable bowel syndrome.
peer_reviewed_research
2012 · study · Temporal status not established
Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
peer_reviewed_research
2012 · study · Temporal status not established
A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
peer_reviewed_research
2012 · study · Temporal status not established
Linaclotide in the management of gastrointestinal tract disorders.
peer_reviewed_research
2012 · study · Temporal status not established
Linaclotide: first global approval.
peer_reviewed_research
2012 · study · Temporal status not established
Linaclotide
other
2012 · study · Temporal status not established
Elvitegravir/cobicistat, mirabegron, and linaclotide.
peer_reviewed_research
2012 · study · Temporal status not established
Linaclotide (Linzess) for constipation.
peer_reviewed_research
2012 · study · Temporal status not established
Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints.
peer_reviewed_research
2012 · study · Temporal status not established
Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.
peer_reviewed_research
2013 · study · Temporal status not established
Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
peer_reviewed_research
2013 · study · Temporal status not established
An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.
peer_reviewed_research
2013 · study · Temporal status not established
Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity.
peer_reviewed_research
2013 · study · Temporal status not established
Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
peer_reviewed_research
2013 · study · Temporal status not established
Linaclotide for constipation-predominant IBS.
peer_reviewed_research
2013 · study · Temporal status not established
Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
peer_reviewed_research
2013 · study · Temporal status not established
A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.
peer_reviewed_research
2013 · study · Temporal status not established
Challenges of managing pain in constipation-predominant IBS: clinical perspectives on antinociceptive actions of linaclotide.
peer_reviewed_research
2013 · study · Temporal status not established
Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.
peer_reviewed_research
2013 · study · Temporal status not established
[Joint Statement of the German Society for Digestive and Metabolic Diseases (DGVS), the German Society for Neurogastroenterology and motility (DGNM) and the German Society for Internal Medicine (DGIM) for linaclotide-benefit assessment of the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with § 35a SGB V (dossier evaluation)].
systematic_review_or_meta_analysis
2013 · study · Temporal status not established
Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.
peer_reviewed_research
2013 · study · Temporal status not established
Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation.
systematic_review_or_meta_analysis
2013 · study · Temporal status not established
Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
systematic_review_or_meta_analysis
2013 · study · Temporal status not established
Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
peer_reviewed_research
2013 · study · Temporal status not established
Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.
peer_reviewed_research
2013 · study · Temporal status not established
Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
peer_reviewed_research
2013 · study · Temporal status not established
Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
peer_reviewed_research
2014 · study · Temporal status not established
The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.
peer_reviewed_research
2014 · study · Temporal status not established
Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C.
peer_reviewed_research
2014 · study · Temporal status not established
Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.
peer_reviewed_research
2014 · study · Temporal status not established
Linaclotide. A bacterial enterotoxin derivative with a laxative action, nothing more.
peer_reviewed_research
2014 · study · Temporal status not established
Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.
peer_reviewed_research
2014 · study · Temporal status not established
Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.
peer_reviewed_research
2014 · study · Temporal status not established
Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide.
peer_reviewed_research
2014 · study · Temporal status not established
Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.
peer_reviewed_research
2014 · study · Temporal status not established
Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.
systematic_review_or_meta_analysis
2014 · study · Temporal status not established
Review article: Linaclotide for the management of irritable bowel syndrome with constipation.
peer_reviewed_research
2015 · study · Temporal status not established
Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.
peer_reviewed_research
2015 · study · Temporal status not established
A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa.
peer_reviewed_research
2015 · study · Temporal status not established
MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
peer_reviewed_research
2015 · study · Temporal status not established
Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
peer_reviewed_research
2016 · study · Temporal status not established
Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland.
peer_reviewed_research
2016 · study · Temporal status not established
Economic Evaluation of Linaclotide for the Treatment of Adult Patients With Chronic Idiopathic Constipation in the United States.
peer_reviewed_research
2017 · study · Temporal status not established
Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.
peer_reviewed_research
2017 · study · Temporal status not established
Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
peer_reviewed_research
2017 · study · Temporal status not established
Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention.
peer_reviewed_research
2018 · study · Temporal status not established
Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
peer_reviewed_research
2018 · study · Temporal status not established
A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
peer_reviewed_research
2018 · study · Temporal status not established
Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
peer_reviewed_research
2018 · study · Temporal status not established
Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
peer_reviewed_research
2018 · study · Temporal status not established
Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
peer_reviewed_research
2018 · study · Temporal status not established
Randomized, double-blind, placebo-controlled study vs data in the daily practice using linaclotide in patients with irritable bowel syndrome with constipation.
peer_reviewed_research
2018 · study · Temporal status not established
Linaclotide inhibits colonic and urinary bladder hypersensitivity in adult female rats following unpredictable neonatal stress.
peer_reviewed_research
2018 · study · Temporal status not established
Long-term results of linaclotide in the treatment of constipation-type irritable bowel syndrome.
peer_reviewed_research
2018 · study · Temporal status not established
Health Care Resource Use and Costs Pre- and Post-Treatment Initiation With Linaclotide: Retrospective Analyses of a U.S. Insured Population.
peer_reviewed_research
2018 · study · Temporal status not established
Linaclotide Attenuates Visceral Organ Crosstalk: Role of Guanylate Cyclase-C Activation in Reversing Bladder-Colon Cross-Sensitization.
peer_reviewed_research
2018 · study · Temporal status not established
Linaclotide improves gastrointestinal transit in cystic fibrosis mice by inhibiting sodium/hydrogen exchanger 3.
peer_reviewed_research
2018 · study · Temporal status not established
Chronic linaclotide treatment reduces colitis-induced neuroplasticity and reverses persistent bladder dysfunction.
peer_reviewed_research
2018 · study · Temporal status not established
Efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in a real‑world setting - results from a German noninterventional study.
peer_reviewed_research
2018 · study · Temporal status not established
Linaclotide for the treatment of chronic constipation.
peer_reviewed_research
2018 · study · Temporal status not established
Efficacy of linaclotide in irritable bowel syndrome with constipation: Real-world data.
peer_reviewed_research
2019 · study · Temporal status not established
High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan.
peer_reviewed_research
2019 · study · Temporal status not established
Safety and tolerability of linaclotide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: pooled Phase 3 analysis.
peer_reviewed_research
2019 · study · Temporal status not established
The Impact of Stool Consistency on Bowel Movement Satisfaction in Patients With IBS-C or CIC Treated With Linaclotide or Other Medications: Real-World Evidence From the CONTOR Study.
peer_reviewed_research
2019 · study · Temporal status not established
Linaclotide treatment reduces endometriosis-associated vaginal hyperalgesia and mechanical allodynia through viscerovisceral cross-talk.
peer_reviewed_research
2019 · study · Temporal status not established
Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms.
peer_reviewed_research
2019 · study · Temporal status not established
[Pharmacological and clinical profile of linaclotide (Linzess<sup>®</sup>), a novel therapeutic agent for irritable bowel syndrome with constipation and chronic constipation].
peer_reviewed_research
2019 · study · Temporal status not established
Linaclotide increases cecal pH, accelerates colonic transit, and increases colonic motility in irritable bowel syndrome with constipation.
peer_reviewed_research
2019 · study · Temporal status not established
Effectiveness and tolerability of linaclotide in the treatment of IBS-C in a "real-life" setting: Results from a Portuguese single-center study.
peer_reviewed_research
2019 · study · Temporal status not established
Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study.
peer_reviewed_research
2019 · study · Temporal status not established
Single-Dose Linaclotide Is Equal in Efficacy to Polyethylene Glycol for Bowel Preparation Prior to Capsule Endoscopy.
peer_reviewed_research
2019 · study · Temporal status not established
Long-term treatment with linaclotide of intestinal pseudo-obstruction secondary to Ehlers-Danlos syndrome.
peer_reviewed_research
2020 · study · Temporal status not established
Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
peer_reviewed_research
2020 · study · Temporal status not established
Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study.
peer_reviewed_research
2020 · study · Temporal status not established
The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease.
peer_reviewed_research
2020 · study · Temporal status not established
Tadalafil versus linaclotide in gastrointestinal dysfunction and depressive behavior in constipation-predominant irritable bowel syndrome.
peer_reviewed_research
2021 · study · Temporal status not established
Polyethylene glycol combined with linaclotide is an effective and well-tolerated bowel preparation regimen for colonoscopy: an endoscopist-blinded, randomized, controlled trial.
peer_reviewed_research
2021 · study · Temporal status not established
Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation.
peer_reviewed_research
2021 · study · Temporal status not established
[Efficacy and Safety of Linaclotide in Elderly Patients].
peer_reviewed_research
2021 · study · Temporal status not established
The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review.
peer_reviewed_research
2021 · study · Temporal status not established
Improving the Gastrointestinal Stability of Linaclotide.
peer_reviewed_research
2021 · study · Temporal status not established
Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis.
peer_reviewed_research
2021 · study · Temporal status not established
Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System.
peer_reviewed_research
2022 · study · Temporal status not established
Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.
peer_reviewed_research
2022 · study · Temporal status not established
Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China.
peer_reviewed_research
2022 · study · Temporal status not established
Linaclotide utilization and potential for off-label use and misuse in three European countries.
peer_reviewed_research
2022 · study · Temporal status not established
Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome with Constipation in China.
peer_reviewed_research
2022 · study · Temporal status not established
Effects of linaclotide in the treatment of chronic constipation and irritable bowel syndrome with constipation: a meta-analysis.
peer_reviewed_research
2023 · study · Temporal status not established
Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials.
peer_reviewed_research
2023 · study · Temporal status not established
A novel ultra-low-volume regimen combining 1 L polyethylene glycol and linaclotide versus 2 L polyethylene glycol for colonoscopy cleansing in low-risk individuals: a randomized controlled trial.
peer_reviewed_research
2023 · study · Temporal status not established
Microbiota-derived butyrate dampens linaclotide stimulation of the guanylate cyclase C pathway in patient-derived colonoids.
peer_reviewed_research
2023 · study · Temporal status not established
A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide.
peer_reviewed_research
2023 · study · Temporal status not established
Cost impact of incorporating linaclotide into low-volume colonoscopy preparation.
peer_reviewed_research
2023 · study · Temporal status not established
Linaclotide (Linzess) for functional constipation.
peer_reviewed_research
2023 · study · Temporal status not established
Editorial: repurposed linaclotide and the quest for abdominal pain management in irritable bowel syndrome.
peer_reviewed_research
2024 · study · Temporal status not established
Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
peer_reviewed_research
2024 · study · Temporal status not established
Linaclotide for functional constipation in paediatric patients: phase III results.
peer_reviewed_research
2024 · study · Temporal status not established
Randomized controlled trial of linaclotide in children aged 6-17 years with functional constipation.
peer_reviewed_research
2024 · study · Temporal status not established
Application of linaclotide in bowel preparation for colonoscopy in patients with constipation: A prospective randomized controlled study.
peer_reviewed_research
2024 · study · Temporal status not established
Efficacy of linaclotide in combination with polyethylene glycol for bowel preparation in Chinese patients undergoing colonoscopy polypectomy: protocol for a randomised controlled trial.
peer_reviewed_research
2024 · study · Temporal status not established
Safety and efficacy of linaclotide in children aged 2-5 years with functional constipation: Phase 2, randomized study.
peer_reviewed_research
2024 · study · Temporal status not established
Evaluation of the efficacy of polyethylene glycol in combination with different doses of linaclotide in a fractionated bowel preparation for colonoscopy: a prospective randomized controlled study.
peer_reviewed_research
2024 · study · Temporal status not established
Efficacy of Polyethylene Glycol Electrolyte Powder Combined With Linaclotide for Colon Cleansing in Patients With Chronic Constipation Undergoing Colonoscopy: A Multicenter, Single-Blinded, Randomized Controlled Trial.
peer_reviewed_research
2024 · study · Temporal status not established
Ten years of successful linaclotide treatment in a patient with intestinal pseudo-obstruction due to Ehlers-Danlos syndrome.
peer_reviewed_research
2024 · study · Temporal status not established
Bowel preparation with linaclotide and 1 L polyethylene glycol plus ascorbic acid prior to colonoscopy in chronic constipated patients.
peer_reviewed_research
2024 · study · Temporal status not established
The Effects of Combined Use of Linaclotide and Polyethylene Glycol Electrolyte Powder in Colonoscopy Preparation for Patients With Chronic Constipation.
peer_reviewed_research
2024 · study · Temporal status not established
Renoprotective effects of laxative linaclotide: Inhibition of acute kidney injury and fibrosis in a rat model of renal ischemia-reperfusion.
peer_reviewed_research
2024 · study · Temporal status not established
DRA involvement in linaclotide-stimulated bicarbonate secretion during loss of CFTR function.
peer_reviewed_research
2024 · study · Temporal status not established
Examining linaclotide for the treatment of chronic idiopathic constipation.
peer_reviewed_research
2024 · study · Temporal status not established
Comparative profiles of lubiprostone, linaclotide, and elobixibat for chronic constipation: a systematic literature review with meta-analysis and number needed to treat/harm.
systematic_review_or_meta_analysis
2024 · study · Temporal status not established
The gut microbiota participates in the effect of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C): a multicenter, prospective, pre-post study.
peer_reviewed_research
2024 · study · Temporal status not established
Linaclotide
other
2024 · study · Temporal status not established
Safety and efficacy of linaclotide in children aged 7-17 years with irritable bowel syndrome with constipation.
peer_reviewed_research
2024 · study · Temporal status not established
Linaclotide for paediatric functional constipation.
peer_reviewed_research
2024 · study · Temporal status not established
Efficacy and safety of linaclotide in treatment-resistant chronic constipation: A multicenter, open-label study.
peer_reviewed_research
2025 · study · Temporal status not established
Effects of the combined use of linaclotide and oral sulfate solution in bowel preparation for patients with chronic constipation undergoing colonoscopy: protocol of a prospective, randomised, controlled, single-blind clinical trial from a single centre in China.
peer_reviewed_research
2025 · study · Temporal status not established
Efficacy of Linaclotide in Functional Dyspepsia and Constipation-Predominant Irritable Bowel Syndrome Overlap: A Randomized Trial.
peer_reviewed_research
2025 · study · Temporal status not established
Efficacy of 1 L Polyethylene Glycol Plus Ascorbic Acid With Linaclotide Versus Senna for Bowel Preparation: A Multicenter, Endoscopist-Blinded, Randomized Controlled Trial (Apple Trial).
peer_reviewed_research
2025 · study · Temporal status not established
Linaclotide Use for the Treatment of Constipation and Gastrointestinal Symptoms in People With Cystic Fibrosis.
peer_reviewed_research
2025 · study · Temporal status not established
Real-world safety of linaclotide in Chinese patients with irritable bowel syndrome with constipation: a multicenter, single-arm, prospective observational study.
peer_reviewed_research
2025 · study · Temporal status not established
Cost-Effectiveness of Vibrant System vs. Linaclotide in Chronic Idiopathic Constipation.
peer_reviewed_research
2025 · study · Temporal status not established
Characterization of disulfide bridges containing cyclic peptide Linaclotide and its degradation products by using LC-HRMS/MS.
peer_reviewed_research
2025 · study · Temporal status not established
Efficacy and Safety of Linaclotide as an Adjunct to Polyethylene Glycol in Bowel Preparation: A Meta-Analysis.
peer_reviewed_research
2025 · study · Temporal status not established
Combined linaclotide and polyethylene glycol electrolyte for colonoscopy preparation: a network meta-analysis of 14 randomized controlled trials.
systematic_review_or_meta_analysis
2025 · study · Temporal status not established
Safety and efficacy of linaclotide as an adjuvant for bowel preparation: A systematic review and meta-analysis.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
Efficacy and Safety of Linaclotide in Pediatric Patients of Functional Constipation: A Meta-analysis of Randomized Controlled Trials.
peer_reviewed_research
2026 · study · Temporal status not established
Effect of 3-Day Linaclotide Administration to Reduce the Polyethylene Glycol Volume for Colonoscopy Bowel Preparation: A Multicenter, Noninferiority, Randomized Controlled Trial.
peer_reviewed_research
2026 · study · Temporal status not established
Short-term linaclotide plus polyethylene glycol in patients at increased risk of inadequate bowel preparation: A randomized, double-blind, multicenter trial.
peer_reviewed_research
2026 · study · Temporal status not established
Effect of Linaclotide on Colonic Motility Assessed With Intraluminal Colonic High-Resolution Manometry in Healthy Subjects. An Acute, Open Label, Randomized, Crossover, Reader-Blinded Study.
peer_reviewed_research
2026 · study · Temporal status not established
Linaclotide in combination with compound polyethylene glycol powder enhances bowel preparation for colonoscopy in patients aged over 60 years: a multi-center, endoscopist-blind, randomized controlled trial.
peer_reviewed_research
2026 · study · Temporal status not established
Identification and Quantification of Structurally Related Peptide Impurity in Linaclotide by Liquid Chromatography-High Resolution Mass Spectrometry.
peer_reviewed_research
2026 · study · Temporal status not established
The Efficacy of Single Dose Linaclotide in Polyethylene Glycol-Based Bowel Preparation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle.
peer_reviewed_research
2026 · study · Temporal status not established
Effect of Age and Age-Defined Menopausal Status on Linaclotide Efficacy and Safety in Adults With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation: Post Hoc Analyses of Phase 2b/3 Studies.
peer_reviewed_research
2026 · study · Temporal status not established
Linaclotide combined with polyethylene glycol for bowel preparation in colonoscopy: a systematic review and meta-analysis of randomized controlled trials.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
Effect of linaclotide combined with polyethylene glycol on bowel preparation before colonoscopy in patients with constipation.
peer_reviewed_research
2026 · study · Temporal status not established
Adjunctive linaclotide improves bowel cleansing and patient experience in polyethylene glycol-based bowel preparation.
peer_reviewed_research
2026 · study · Temporal status not established
Evaluating linaclotide for the treatment of irritable bowel syndrome with constipation in children and adolescents.
peer_reviewed_research
2026 · study · Temporal status not established
Efficacy safety of linaclotide combined with polyethylene glycol for bowel preparation in patients with constipation: a meta-analysis.
systematic_review_or_meta_analysis
2026 · study · Temporal status not established
A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders.
peer_reviewed_research
2026 · study · Temporal status not established
Evaluating linaclotide for the treatment of functional constipation in children and adolescents.
peer_reviewed_research
2026 · regulatory · Temporal status not established
Regulatory review: approved
European Union — EMA
2026 · regulatory · Temporal status not established
Regulatory review: approved
United States — FDA

The represented chronology reflects records currently included in the governed dataset and does not claim to represent the entire scientific literature.

What still needs investigation

Claim traceability

No institutional claim record is currently represented for this peptide.

Evidence is missing or not represented as studied; this is not a conclusion that the intervention does not work.

Linaclotide research, ranked and separated by purpose

Linaclotide: what this atlas does and does not establish

Practice-defining evidence

Strong supporting evidence

Contextual evidence

Signal-generating evidence

Suggested citation

No community pattern is displayed yet

The state of the record

Evidence, claims, and boundaries

6 conclusions connected to 0 featured studies

Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Linaclotide for functional constipation in paediatric patients: phase III results.

Chemistry and represented biological context

Molecular and structural record

Continue through the research system

Research discovery

How the scientific record is developing

Research chronology

Linaclotide

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.

Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation.

Pilot study on the effect of linaclotide in patients with chronic constipation.

Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.

Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.

Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.

Molecule of the month. Linaclotide acetate.

Efficacy of linaclotide for patients with chronic constipation.

Linaclotide - a secretagogue and antihyperalgesic agent - what next?

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation.

Constipation: Linaclotide--a stimulating new drug for chronic constipation.

Two randomized trials of linaclotide for chronic constipation.

Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.

Optimized Fmoc solid-phase synthesis of the cysteine-rich peptide linaclotide.

The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.

Linaclotide: a novel approach to the treatment of irritable bowel syndrome.

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.

Linaclotide in the management of gastrointestinal tract disorders.

Linaclotide: first global approval.

Linaclotide

Elvitegravir/cobicistat, mirabegron, and linaclotide.

Linaclotide (Linzess) for constipation.

Linaclotide: promising IBS-C efficacy in an era of provisional study endpoints.

Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.

Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.

An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.

Linaclotide in the treatment of patients with irritable bowel syndrome and constipation - analysis of an opportunity.

Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

Linaclotide for constipation-predominant IBS.

Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.

A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation.

Challenges of managing pain in constipation-predominant IBS: clinical perspectives on antinociceptive actions of linaclotide.

Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.

Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.

Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation.

Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.

Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.

Linaclotide: a new option for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation in adults.

Linaclotide-a novel secretagogue in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.

Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.

The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials.

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C.

Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials.

Linaclotide. A bacterial enterotoxin derivative with a laxative action, nothing more.

Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome.

Linaclotide: a review of its use in the treatment of irritable bowel syndrome with constipation.

Clarification of linaclotide pharmacology presented in a recent clinical study of plecanatide.

Effect of linaclotide on severe abdominal symptoms in patients with irritable bowel syndrome with constipation.

Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis.

Review article: Linaclotide for the management of irritable bowel syndrome with constipation.

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.

A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa.

MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.

Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.

Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland.

Economic Evaluation of Linaclotide for the Treatment of Adult Patients With Chronic Idiopathic Constipation in the United States.

Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report.

Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.